drugset / Trial / NCT05682638
A Global Multi-center Clinical Study of SARS-CoV-2 mRNA Vaccine for the Prevention of COVID-19
Phase 3
Unknown
34000 enrolled
AIM Vaccine Co., Ltd.
AIM Innovation Biotechnology (Shanghai) Co., Ltd · collabLiveRNA Therapeutics Inc. · collabNingbo Rongan Biological Pharmaceutical Co., Ltd. · collab
RandomizedParallel-groupTriple-blindPrevention
Summary
A Global Multi-center, Randomized, Blinded, Placebo-controlled Phase 3 Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (LVRNA009) for the Prevention of COVID-19 in Participants Aged 18 Years and Older
Timeline
- Start
- 2023-01-30
- Primary completion
- 2024-12
- Completion
- 2025-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LVRNA009 | Messenger RNA (mRNA) | 100 ug | — |